Hair shedding on a GLP-1: the label rates, why it is tied to weight loss, and what usually happens next

Hair in the shower drain is one of the more alarming things that happens on a GLP-1, and one of the less dangerous. It is on the label, the numbers are small, and the label itself points at the cause. This guide gives the figures, explains the mechanism the pattern fits, and lists the other things a prescriber will want to rule out before blaming the drug.

What the labels report

The Wegovy label's adverse reaction table for adults lists hair loss in 3 percent of people on semaglutide 2.4 mg versus 1 percent on placebo, pooled from STEP 1, 2 and 3. In the separate table for the higher 7.2 mg dose studied later, hair loss was reported in 6 percent versus 1 percent on placebo. In the adolescent trial table, 4 percent versus 0.

The Zepbound label's table lists hair loss in 5, 4 and 5 percent of people on 5, 10 and 15 mg versus 1 percent on placebo, pooled from SURMOUNT-1 and SURMOUNT-2. Uniquely, it adds a paragraph: hair loss adverse reactions in Zepbound-treated patients "were associated with weight reduction", and were reported more often in women than men: 7.1 percent of women versus 0.5 percent of men on Zepbound, compared with 1.3 percent of women and 0 percent of men on placebo. No Zepbound-treated patient discontinued treatment because of hair loss; one placebo patient did.

The Ozempic and Mounjaro labels, written from the type 2 diabetes trials with smaller weight losses, do not list hair loss in their adverse reaction tables.

Read together, those figures say something specific: the more weight people lost, the more hair loss was reported, and the effect tracked weight loss rather than dose in any simple way (Zepbound 10 mg reported less than 5 mg). That is the signature of an effect of weight loss, not of the molecule.

Telogen effluvium

Hair follicles cycle between a growing phase (anagen) that lasts years and a resting phase (telogen) that lasts a few months, after which the hair is shed and a new one grows. About a tenth of scalp follicles are resting at any time. A significant physiological stress, such as rapid weight loss, a severe illness, surgery, childbirth or a large calorie deficit, can push a much larger share of follicles into the resting phase at once. Two to four months later those hairs shed together, and the shedding is diffuse, across the whole scalp, rather than in patches. That is telogen effluvium. It is the pattern people on GLP-1s describe, it is the pattern seen after bariatric surgery, and it is what the Zepbound label's phrase "associated with weight reduction" points at.

Because the follicles are not damaged, the hairs regrow as the follicles re-enter the growing phase. The shedding usually slows once the trigger has passed, which for weight loss means once the rate of loss has slowed or weight has stabilised, and full density can take six to twelve months to return. None of that timing is in the labels; it is the general course of telogen effluvium described in dermatology.

Things that make it worse, and that a prescriber will check

The label does not investigate causes beyond weight reduction. Clinically, three contributors travel with rapid weight loss on a suppressed appetite and are worth ruling out because they are fixable.

Protein. Hair is keratin, a protein, and a diet that has shrunk to a fraction of its former volume can fall below adequate protein without the person noticing. Reviews of protein needs during weight loss (Cava 2017, PubMed 28507015; Leidy 2015, PubMed 25926512) argue for intakes above the general adult RDA during an energy deficit, mainly to protect muscle; the hair benefits from the same intake. The muscle preservation guide covers targets, and the calculator site turns body weight into a number.

Iron. Low ferritin is a well-recognised contributor to diffuse hair shedding, especially in menstruating women, who are also the group in which the Zepbound label reports most of the hair loss. Reduced red meat intake on a suppressed appetite lowers iron intake. A ferritin level is a simple blood test and a reasonable ask; the lab guide site explains it.

Thyroid. Both under- and over-activity cause hair changes, and thyroid function is routinely checked around weight-loss treatment anyway. Note that the boxed warning on every GLP-1 label concerns thyroid C-cell tumours in rodents and is unrelated to hair; it is mentioned here only because people conflate the two.

Other contributors that are not about the drug: recent illness or surgery, childbirth in the last year, new medications (several common ones cause telogen effluvium), hormonal changes including stopping or starting contraception, and a family pattern of hair thinning that weight loss has unmasked rather than caused.

What to do

Measure rather than worry. Count roughly how many hairs come out in a wash over a week; telogen effluvium is a sustained increase, not a bad day. Note when it started relative to when the weight loss began; a two-to-four-month lag fits the pattern.

Slow down if the rate of loss is very fast. There is no label instruction to do so and no trial that tested it, but rapid loss is the trigger, and the label's own options for delaying escalation or holding at a lower maintenance dose (see the dose escalation guide) exist for tolerability problems, of which this is one. A conversation with your prescriber, not a unilateral change.

Fix the fixable: protein to target every day, a ferritin check, thyroid function if not recently done, and an honest look at what you are actually eating in a week. Be gentle with the hair that remains: less heat, less tension, fewer chemical treatments while it recovers. That is common-sense dermatology advice, not label content.

Give it time. The shedding phase of telogen effluvium is measured in months, and regrowth after it in more months.

What to tell the prescriber

Bring the timeline: when the weight loss started, how fast it has been, when the shedding began, and whether it is diffuse or patchy. Bring a recent medication list including anything started in the last six months, and say whether periods have become heavier or more frequent. Ask for ferritin and thyroid function if they have not been checked, and ask whether the rate of loss is faster than intended. If the answer to the last question is yes, the label's tolerability options, delaying escalation or holding at a lower maintenance dose, are the mechanism for slowing it, and asking for them by name keeps the conversation concrete. The prescriber checklist has these as written questions.

When it is not telogen effluvium

Patchy loss with smooth bald areas, loss with scalp itching, scaling or pain, loss of eyebrows or body hair, broken rather than shed hairs, or shedding that continues more than six months after weight has stabilised: none of these fits the pattern and each needs a clinician, ideally a dermatologist. So does any shedding accompanied by other symptoms, such as fatigue, cold intolerance or heavy periods, that point at iron or thyroid.

Compounded products

Compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with brand products, and no adverse-event rates exist for them; the figures above come from the brand-label trials of the same active ingredients. The mechanism, weight loss, is the same. FormBlends describes what its pharmacies dispense on its semaglutide and tirzepatide pages.